{"transactions":[{"id":676207,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-25T20:06:37.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":9589,"price":15.54,"value":149013.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":63899,"source":{"system":"sec-edgar","filing":"0001327111-26-000006","document":"form4-08252026_080833.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000006/form4-08252026_080833.xml","form_type":"4"}},{"id":690861,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-11T20:07:51.000Z","date":"2026-08-10","kind":"sale","planned":false,"acquired":false,"shares":390,"price":14.34,"value":5592.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $14.22 to $14.34 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":73488,"source":{"system":"sec-edgar","filing":"0001327111-26-000004","document":"form4-08112026_080842.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000004/form4-08112026_080842.xml","form_type":"4"}},{"id":714783,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2026-07-06T22:20:50.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":152207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on July 1, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":152207,"derivative":{"exercise_price":7.85,"expiration_date":"2036-07-01","underlying":"Common Shares","underlying_shares":152207},"source":{"system":"sec-edgar","filing":"0001628280-26-047400","document":"wk-form4_1783376448.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000162828026047400/wk-form4_1783376448.xml","form_type":"4"}},{"id":737865,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-15T22:37:17.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":388,"price":18.91,"value":7337.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $18.91 to $19.15 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":73878,"source":{"system":"sec-edgar","filing":"0001327111-26-000003","document":"form4-06152026_100612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000003/form4-06152026_100612.xml","form_type":"4"}},{"id":907684,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-13T01:47:49.000Z","date":"2026-02-11","kind":"sale","planned":false,"acquired":false,"shares":7455,"price":23.39,"value":174372.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of performance-based vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $23.3939 to $24.7850 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":74266,"source":{"system":"sec-edgar","filing":"0001327111-26-000002","document":"form4-02132026_010246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000002/form4-02132026_010246.xml","form_type":"4"}},{"id":910037,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2026-02-12T02:03:03.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":155000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twelve and one-half percent (12.5%) of the total number of shares of Common Stock\nsubject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the \"Vesting Commencement Date\")\nand thereafter, an additional one forty-eighth (1/48th) of the shares will become vested and exercisable\nmonthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month,\non the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of\nthe shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting\ndate."}],"balance_after":155000,"derivative":{"exercise_price":23.71,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":155000},"source":{"system":"sec-edgar","filing":"0001327111-26-000001","document":"form4-02122026_020200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000001/form4-02122026_020200.xml","form_type":"4"}},{"id":910036,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-12T02:03:03.000Z","date":"2026-02-10","kind":"sale","planned":false,"acquired":false,"shares":438,"price":23.12,"value":10126.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":81721,"source":{"system":"sec-edgar","filing":"0001327111-26-000001","document":"form4-02122026_020200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000001/form4-02122026_020200.xml","form_type":"4"}},{"id":910035,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-12T02:03:03.000Z","date":"2026-02-09","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date."}],"balance_after":82159,"source":{"system":"sec-edgar","filing":"0001327111-26-000001","document":"form4-02122026_020200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711126000001/form4-02122026_020200.xml","form_type":"4"}},{"id":1002094,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-11-13T01:36:42.000Z","date":"2025-11-10","kind":"sale","planned":false,"acquired":false,"shares":412,"price":16.11,"value":6637.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."}],"balance_after":67159,"source":{"system":"sec-edgar","filing":"0001327111-25-000007","document":"form4-11132025_011139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711125000007/form4-11132025_011139.xml","form_type":"4"}},{"id":1012076,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2025-10-29T21:40:13.000Z","date":"2025-10-27","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"12.5% of the option shares will vest on April 27, 2026, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":175000,"derivative":{"exercise_price":17.23,"expiration_date":"2035-10-26","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001327111-25-000006","document":"form4-10292025_091010.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000132711125000006/form4-10292025_091010.xml","form_type":"4"}},{"id":1058272,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-22T20:07:24.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":7257,"price":10.544,"value":76517.808,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."}],"balance_after":67571,"source":{"system":"sec-edgar","filing":"0001415889-25-022747","document":"form4-08222025_080818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925022747/form4-08222025_080818.xml","form_type":"4"}},{"id":1058271,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-22T20:07:24.000Z","date":"2025-08-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 20,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 20,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date."}],"balance_after":74828,"source":{"system":"sec-edgar","filing":"0001415889-25-022747","document":"form4-08222025_080818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925022747/form4-08222025_080818.xml","form_type":"4"}},{"id":1067863,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-14T01:10:46.000Z","date":"2025-08-12","kind":"sale","planned":false,"acquired":false,"shares":406,"price":10.338,"value":4197.228,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.120 to $10.415 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":34828,"source":{"system":"sec-edgar","filing":"0001415889-25-021694","document":"form4-08142025_010843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925021694/form4-08142025_010843.xml","form_type":"4"}},{"id":1067862,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-08-14T01:10:46.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":391,"price":10.526,"value":4115.666,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.045 to $11.00 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split."}],"balance_after":35234,"source":{"system":"sec-edgar","filing":"0001415889-25-021694","document":"form4-08142025_010843.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925021694/form4-08142025_010843.xml","form_type":"4"}},{"id":1083960,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4570,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":106.14,"underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083959,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":63.66,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083958,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":50.64,"underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083957,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":87.13,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083956,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":76.24,"underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083955,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4875,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":96.77,"underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083954,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":69.79,"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083953,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10909,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":46.02,"underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083952,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10909,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":19.53,"underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083951,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21818,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option."}],"balance_after":0,"derivative":{"exercise_price":19.08,"underlying":"Common Stock","underlying_shares":21818},"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083950,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"other","planned":false,"acquired":false,"shares":13254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1083949,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-21T23:48:10.000Z","date":"2025-07-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3902,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (\"Aventis\"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis (\"Purchaser\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for (i) $129.00 per share, without interest (the \"Cash Offer Price\"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a \"CVR\" and together with the Cash Offer Price, the \"Offer Consideration\"). On July 17, 2025 (the \"Effective Time\"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (\"RSU\"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration."}],"balance_after":13254,"source":{"system":"sec-edgar","filing":"0001104659-25-069390","document":"tm2521348-17_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000110465925069390/tm2521348-17_4seq1.xml","form_type":"4"}},{"id":1102491,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T20:25:38.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":3902,"price":128.12,"value":499924.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":17156,"source":{"system":"sec-edgar","filing":"0001415889-25-018082","document":"form4-06242025_080635.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000141588925018082/form4-06242025_080635.xml","form_type":"4"}},{"id":1200125,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-18T22:59:18.000Z","date":"2025-03-14","kind":"purchase","planned":false,"acquired":true,"shares":175000,"price":0.6068,"value":106190.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.59980 to $0.62020, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range."}],"balance_after":712500,"source":{"system":"sec-edgar","filing":"0001415889-25-008509","document":"form4-03182025_100315.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925008509/form4-03182025_100315.xml","form_type":"4"}},{"id":1243441,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:33:46.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon\nthe achievement of specified performance criteria."}],"balance_after":168750,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0001415889-25-005768","document":"form4-02272025_120243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005768/form4-02272025_120243.xml","form_type":"4"}},{"id":1243440,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2025-02-27T00:33:46.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":1350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":1350000,"derivative":{"exercise_price":0.5535,"expiration_date":"2035-02-09","underlying":"Common Stock","underlying_shares":1350000},"source":{"system":"sec-edgar","filing":"0001415889-25-005768","document":"form4-02272025_120243.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005768/form4-02272025_120243.xml","form_type":"4"}},{"id":1243439,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-27T00:33:46.000Z","date":"2025-02-10","kind":"grant","planned":false,"acquired":true,"shares":337500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date."}],"balance_after":537500,"source":{"system":"sec-edgar","filing":"0001415889-25-005768","document":"form4-02272025_120243.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000141588925005768/form4-02272025_120243.xml","form_type":"4"}},{"id":1478687,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T21:35:43.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":4570,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":4570,"derivative":{"exercise_price":106.14,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":4570},"source":{"system":"sec-edgar","filing":"0001415889-24-016983","document":"form4-06142024_090640.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000141588924016983/form4-06142024_090640.xml","form_type":"4"}},{"id":1478686,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T21:35:43.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":2242,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":13254,"source":{"system":"sec-edgar","filing":"0001415889-24-016983","document":"form4-06142024_090640.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000141588924016983/form4-06142024_090640.xml","form_type":"4"}},{"id":1646414,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-02-14T01:17:30.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001209191-24-003269","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919124003269/doc4.xml","form_type":"4"}},{"id":1734754,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:53:17.000Z","date":"2023-11-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent of the shares shall vest on December 15, 2023 and 1/48th of the shares vest in equal monthly installments over the following thirty-six months."}],"balance_after":0,"derivative":{"exercise_price":3.28,"expiration_date":"2032-12-14","underlying":"Common Stock","underlying_shares":7500000},"source":{"system":"sec-edgar","filing":"0001209191-23-056179","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123056179/doc4.xml","form_type":"4"}},{"id":1734753,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-11-21T01:53:17.000Z","date":"2023-11-16","kind":"grant","planned":false,"acquired":true,"shares":7500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing (the \"Option Repricing\") effective on November 16, 2023 (the \"Repricing Date\"). The Option Repricing applies to options with exercise prices greater than $2.37 per share held by all continuing employees of the Issuer as of the Repricing Date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Option Repricing, the exercise price of the repriced options, including the Option, has been amended to reduce the exercise price to $1.87 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. In addition, the vesting schedule for the unvested shares underlying repriced options held by executive officers, including the reporting person, was extended for an additional year. There is no change to the expiration dates of or number of shares underlying the repriced options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty percent of the shares shall vest on December 15, 2023 and 1/60th of the total shares vest in equal monthly installments over the following forty-eight months."}],"balance_after":7500000,"derivative":{"exercise_price":1.87,"expiration_date":"2032-12-14","underlying":"Common Stock","underlying_shares":7500000},"source":{"system":"sec-edgar","filing":"0001209191-23-056179","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919123056179/doc4.xml","form_type":"4"}},{"id":1844988,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-23T23:06:17.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":63.66,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-23-010262","document":"form4-06232023_110612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000141588923010262/form4-06232023_110612.xml","form_type":"4"}},{"id":1844987,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-23T23:06:17.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":11012,"source":{"system":"sec-edgar","filing":"0001415889-23-010262","document":"form4-06232023_110612.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000141588923010262/form4-06232023_110612.xml","form_type":"4"}},{"id":2081818,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Option (right to buy)","published_at":"2022-12-19T21:20:33.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":7500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five (25) percent of the shares subject to the option shall vest on December 15, 2023 and 1/48th of the shares subject to the option shall vest in equal monthly installments thereafter until all shares are vested, subject to the reporting person remaining an employee of the Issuer on each applicable vesting date."}],"balance_after":7500000,"derivative":{"exercise_price":3.28,"expiration_date":"2032-12-14","underlying":"Common Stock","underlying_shares":7500000},"source":{"system":"sec-edgar","filing":"0001209191-22-061898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122061898/doc4.xml","form_type":"4"}},{"id":2218551,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T01:52:41.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":5300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":5300,"derivative":{"exercise_price":50.64,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":5300},"source":{"system":"sec-edgar","filing":"0001415889-22-007128","document":"form4-06302022_060628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000141588922007128/form4-06302022_060628.xml","form_type":"4"}},{"id":2218550,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-01T01:52:41.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":8412,"source":{"system":"sec-edgar","filing":"0001415889-22-007128","document":"form4-06302022_060628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000141588922007128/form4-06302022_060628.xml","form_type":"4"}},{"id":2236202,"issuer":{"id":5757,"kind":"organization","name":"Lyell Immunopharma, Inc.","symbol":"LYEL"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2022-06-10T20:16:46.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 8, 2022 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected\nor the Reporting Person not standing for re-election); or (b) the first anniversary of June 8, 2022, subject to the Reporting Person\nproviding continuous service through such date."}],"balance_after":65000,"derivative":{"exercise_price":5.31,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001209191-22-035866","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1806952/000120919122035866/doc4.xml","form_type":"4"}},{"id":2680588,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T20:16:28.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022."}],"balance_after":4500,"derivative":{"exercise_price":87.13,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-21-006416","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911021006416/edgar.xml","form_type":"4"}},{"id":2680587,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-04T20:16:28.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":5812,"source":{"system":"sec-edgar","filing":"0001179110-21-006416","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911021006416/edgar.xml","form_type":"4"}},{"id":3098322,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-26T20:09:53.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021."}],"balance_after":4500,"derivative":{"exercise_price":76.24,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001179110-20-007792","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911020007792/edgar.xml","form_type":"4"}},{"id":3098321,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-26T20:09:53.000Z","date":"2020-06-24","kind":"grant","acquired":true,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":3562,"source":{"system":"sec-edgar","filing":"0001179110-20-007792","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911020007792/edgar.xml","form_type":"4"}},{"id":3101704,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-06-23T20:14:30.000Z","date":"2020-06-19","kind":"exercise","acquired":false,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-20-007718","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911020007718/edgar.xml","form_type":"4"}},{"id":3101703,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-23T20:14:30.000Z","date":"2020-06-19","kind":"exercise","acquired":true,"shares":1312,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."}],"balance_after":1312,"source":{"system":"sec-edgar","filing":"0001179110-20-007718","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911020007718/edgar.xml","form_type":"4"}},{"id":3180422,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-04-07T21:16:33.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":302693,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":302693,"derivative":{"exercise_price":8.08,"expiration_date":"2030-04-02","underlying":"Common Shares","underlying_shares":302693},"source":{"system":"sec-edgar","filing":"0001209191-20-023797","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000120919120023797/doc4.xml","form_type":"4"}},{"id":3180421,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2020-04-07T21:16:33.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":197659,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units (\"RSUs\") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":1043824,"source":{"system":"sec-edgar","filing":"0001209191-20-023797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000120919120023797/doc4.xml","form_type":"4"}},{"id":3482259,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-06-20T20:42:07.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":1312,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":1312,"derivative":{"underlying":"Common Stock","underlying_shares":1312},"source":{"system":"sec-edgar","filing":"0001179110-19-007987","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911019007987/edgar.xml","form_type":"4"}},{"id":3482258,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-20T20:42:07.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":4875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020."}],"balance_after":4875,"derivative":{"exercise_price":96.77,"expiration_date":"2029-06-19","underlying":"Common Stock","underlying_shares":4875},"source":{"system":"sec-edgar","filing":"0001179110-19-007987","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911019007987/edgar.xml","form_type":"4"}},{"id":3559167,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-09T22:12:19.000Z","date":"2019-04-05","kind":"grant","acquired":true,"shares":330660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":330660,"derivative":{"exercise_price":24.44,"expiration_date":"2029-05-04","underlying":"Common Stock","underlying_shares":330660},"source":{"system":"sec-edgar","filing":"0001209191-19-024130","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000120919119024130/doc4.xml","form_type":"4"}},{"id":3883871,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-25T20:57:18.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019."}],"balance_after":51136,"derivative":{"exercise_price":69.79,"expiration_date":"2028-06-21","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001179110-18-009003","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911018009003/edgar.xml","form_type":"4"}},{"id":3960822,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-04-18T22:41:28.000Z","date":"2018-04-16","kind":"grant","acquired":true,"shares":248450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the common shares underlying this option vest on April 16, 2019, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter measured from April 16, 2019, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date."}],"balance_after":248450,"derivative":{"exercise_price":21.87,"expiration_date":"2028-04-15","underlying":"Common Shares","underlying_shares":248450},"source":{"system":"sec-edgar","filing":"0001209191-18-025454","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000120919118025454/doc4.xml","form_type":"4"}},{"id":4273313,"issuer":{"id":77326,"kind":"organization","name":"Blueprint Medicines Corp","symbol":"BPMC"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-23T20:22:16.000Z","date":"2017-06-21","kind":"grant","acquired":true,"shares":10909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2018."}],"balance_after":43636,"derivative":{"exercise_price":46.02,"expiration_date":"2027-06-21","underlying":"Common Stock","underlying_shares":10909},"source":{"system":"sec-edgar","filing":"0001179110-17-009517","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000117911017009517/edgar.xml","form_type":"4"}},{"id":4295355,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Common Shares","published_at":"2017-06-02T22:35:51.000Z","date":"2017-05-31","kind":"grant","acquired":true,"shares":564111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"1/3 of the shares will vest if the Issuer's stock price exceeds $30.00 per share for a continuous 5-day volume-weighted average price (\"VWAP\") period, an additional 1/3 of the shares will vest if the Issuer's stock price exceeds $60.00 per share for a continuous 5-day VWAP period, and the final 1/3 of the shares will vest if the Issuer's stock price exceeds $90.00 per share for a continuous 5-day VWAP period, provided the Reporting Person has provided continuous service to Myovant Sciences, Inc. or its affiliates on the date of each vesting milestone."}],"balance_after":1692333,"source":{"system":"sec-edgar","filing":"0001209191-17-037462","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000120919117037462/doc4.xml","form_type":"4"}},{"id":4315324,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":19932,"kind":"person","name":"Seely Lynn","position":1,"cik":"0001327111","reported_name":"Seely Lynn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-17T21:11:12.000Z","date":"2017-05-15","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest and become exercisable on May 15, 2018; the balance of the shares vest and become exercisable in a series of twelve (12) successive equal quarterly installments measured from May 15, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date."}],"balance_after":400000,"derivative":{"exercise_price":12.68,"expiration_date":"2027-05-14","underlying":"Common Shares","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-17-033228","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1327111/000120919117033228/doc4.xml","form_type":"4"}}]}